Search

Your search keyword '"Fabio Fimiani"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Fabio Fimiani" Remove constraint Author: "Fabio Fimiani"
72 results on '"Fabio Fimiani"'

Search Results

1. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options

2. Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

3. MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease

4. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

5. Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

6. Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

7. An Overview of Molecular Mechanisms in Fabry Disease

8. Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes

9. Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge

10. Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies

11. Methicillin-Resistant Staphylococcus aureus: Risk for General Infection and Endocarditis Among Athletes

12. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy

13. Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

14. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

15. The Risk of Sudden Unexpected Cardiac Death in Children

16. Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia

17. MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease

18. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

19. Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

20. Initial Invasive or Conservative Strategy for Stable Coronary Disease

21. The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota

22. The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers

23. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies

24. 785 Sodium–glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk

25. 760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry

26. Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group

27. New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia

28. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

29. Health status after invasive or conservative care in coronary and advanced kidney disease

30. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease

31. Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes

32. Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination

33. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry

34. Multidisciplinary in-depth investigation in a young athlete suffering from syncope caused by myocardial bridge

35. Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile

36. Clinical outcome with NOACs vs VKAs in patients with atrial fibrillation and severe chronic kidney disease: results of a retrospective, multicenter, real-world study

37. Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease

38. Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies

39. Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study

40. Methicillin-Resistant Staphylococcus aureus: Risk for General Infection and Endocarditis Among Athletes

41. Methicillin-Resistant

42. Improving adherence to ticagrelor in patients after acute coronary syndrome: Results from the progress trial

43. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition

44. Childhood obesity: an overview of laboratory medicine, exercise and microbiome

45. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk

46. ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial

47. Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry)

48. Laboratory medicine: Health evaluation in elite athletes

49. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience

50. Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement

Catalog

Books, media, physical & digital resources